Nathan Connell: Is It Time to Rethink What We Tell Hemophilia B Carriers About Pregnancy?
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn about a recent article by Claire Kelly et al, published in JTH, adding:
”Is it time to rethink what we tell hemophilia B carriers about pregnancy?
For years, guidelines have stated that factor IX levels do NOT rise during pregnancy in hemophilia B carriers, unlike factor VIII in hemophilia A carriers.
This has driven more conservative management, such as earlier planning for factor concentrate, and in some cases, ruling out neuraxial anesthesia.
But here’s the thing, that guidance was based on data from only around 30 carriers across 10 publications, many of which were isolated case reports.
A new Irish registry study by Kelly et al. in the Journal of Thrombosis and Haemostasis (JTH) examined 49 hemophilia B carriers across 87 pregnancies, the largest cohort to date, and noted:
- FIX levels DID rise significantly during pregnancy (mean 0.54 → 0.89 IU/mL, p < 0.0001)
- Even in women with mild hemophilia B (baseline <0.40), levels increased meaningfully (0.27 → 0.51 IU/mL)
- Every carrier with a baseline FIX between 0.30–0.49 reached levels >0.50, which may be enough for neuraxial anesthesia
Why does this matter?
We may have been overcorrecting. Some of these women were likely told they couldn’t have an epidural, or were given factor concentrate they may not have needed.
This study suggests that with proper third-trimester level monitoring, many hemophilia B carriers, especially those with mild disease, can be managed less conservatively than current guidelines recommend.
This doesn’t change the picture for carriers with very low baseline levels, where the rise may still be insufficient.
But for a meaningful proportion of carriers, it opens the door to safer, more patient-centered care.
Bottom line: Check the levels. Don’t assume they won’t rise. The data now say otherwise.”
Title: Contrary to current guidance, antenatal factor IX levels increase in female carriers of hemophilia B
Authors: Claire Kelly, Janet Cleary, Catriona Keenan, Isabelle Delachapelle, Leona Connolly, Mary Byrne, Mairead O’Donovan, Niamh M. O’Connell, James S. O’Donnell, Kevin Ryan, Michelle Lavin

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants